Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of CAbozantinib in Combination with AtezolizumaB As NeoAdjuvant Treatment for Muscle-Invasive BladdEr Cancer

NCT04289779 is registered in ClinicalTrials.gov with Deepak Kilari as lead sponsor.

NCT NCT04289779
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04289779 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of CAbozantinib in Combination with AtezolizumaB As NeoAdjuvant Treatment for Muscle-Invasive BladdEr Cancer
Lead sponsor
Deepak Kilari
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 21, 2020
Completion date
December 31, 2025
Enrollment
46 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer